ICRM
PBYI icon

Insight Capital Research & Management’s Puma Biotechnology PBYI Stock Holding History

Insight Capital Research & Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,044
Closed -$525K – 144
2014
Q1 		$525K Buy
+5,044
New +$593K 0.12% 112

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Insight Capital Research & Management's PBYI Position: Q2 2014 in Review

Insight Capital Research & Management sold out of Puma Biotechnology (PBYI) in Q2 2014, closing a stake of 5,044 shares — an estimated $525K sold.

Insight Capital Research & Management first reported a position in PBYI in Q1 2014 and held it in 1 quarter. The position peaked at $525K in Q1 2014. 137 funds tracked by Wall St. Rank hold PBYI as of Q2 2014.

  • Insight Capital Research & Management reported no remaining Puma Biotechnology position as of Q2 2014 after selling out during the quarter.
  • Insight Capital Research & Management sold 5,044 Puma Biotechnology shares in Q2 2014, an estimated $525K.
  • Insight Capital Research & Management first reported a position in Puma Biotechnology in Q1 2014 and held it in 1 quarter.
  • Insight Capital Research & Management's Puma Biotechnology position peaked at $525K in Q1 2014.
  • 137 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2014.

Based on Insight Capital Research & Management's 13F filing for Q2 2014, filed 13 Aug 2014.